liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Composition and functionality of the intrahepatic innate lymphoid cell-compartment in human nonfibrotic and fibrotic livers
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Karolinska Institute, Sweden.
Show others and affiliations
2017 (English)In: European Journal of Immunology, ISSN 0014-2980, E-ISSN 1521-4141, Vol. 47, no 8, 1280-1294 p.Article in journal (Refereed) Published
Abstract [en]

Human innate lymphoid cells have been described to exist in different organs, with functional deregulation of these cells contributing to several disease states. Here, we performed the first detailed characterization of the phenotype, tissue-residency properties, and functionality of ILC1s, ILC2s, and ILC3s in the human adult and fetal liver. In addition, we investigated changes in the ILC compartment in liver fibrosis. A unique composition of tissue-resident ILCs was observed in nonfibrotic livers as compared with that in mucosal tissues, with NKp44(-) ILC3s accounting for the majority of total intrahepatic ILCs. The frequency of ILC2s, representing a small fraction of ILCs in nonfibrotic livers, increased in liver fibrosis and correlated directly with the severity of the disease. Notably, intrahepatic ILC2s secreted the profibrotic cytokine IL-13 when exposed to IL-33 and thymic stromal lymphopoetin (TSLP); these cytokines were produced by hepatocytes, hepatic stellate cells (HSCs), and Kupffer cells in response to TLR-3 stimulation. In summary, the present results provide the first detailed characterization of intrahepatic ILCs in human adult and fetal liver. The results indicate a role for ILC2s in human liver fibrosis, implying that targeting ILC2s might be a novel therapeutic strategy for its treatment.

Place, publisher, year, edition, pages
WILEY , 2017. Vol. 47, no 8, 1280-1294 p.
Keyword [en]
Innate lymphoid cells; Liver; Fibrosis; Human; Tissue-residency
National Category
Immunology
Identifiers
URN: urn:nbn:se:liu:diva-140519DOI: 10.1002/eji.201646890ISI: 000407262000006PubMedID: 28613415OAI: oai:DiVA.org:liu-140519DiVA: diva2:1140110
Note

Funding Agencies|Swedish Research Council [524-2010-6770, 524-2012-2682, 521-2013-2791]; Swedish Cancer Society [120108, 130396]; Swedish Society for Medical Research; Foundation for Strategic Research [ICA12-0023]

Available from: 2017-09-11 Created: 2017-09-11 Last updated: 2017-09-11

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Mjösberg, Jenny
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health Sciences
In the same journal
European Journal of Immunology
Immunology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 12 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf